Avsar.

Healthcare · Pharmaceuticals

Senores Pharmaceuticals Ltd (SENORES)

₹1,522.40

Mkt cap
₹6,897 Cr
P/E ratio
54.60
P/B
7.50
Div yield
0.00%
ROE
13.40%
ROCE
15.10%
EPS (TTM)
₹27.88
Book value
₹203
52W range
674–1,551
Sector
Healthcare

Price history

Previous close

Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities [1]

NSE SENORESBSE 544319
Health check
Constructive
ValuationExpensive
ProfitabilityAverage
GrowthHigh
TechnicalsBullish
52-week range
−1.84% from high
₹1,522
₹674+126.01% from low₹1,551
Current
₹1,522.40
Prev close
₹1,510.00
Day
+0.82%
Price performance
1D
+0.82%
1W
+4.65%
1M
+7.05%
3M
+36.83%
6M
+106.22%
1Y
+118.58%
YTD
+75.94%

Financials

Revenue, profit & margin
P/E ratio
54.6×
SENORES is 56% above the sector median of 35.1×
SENORES54.6×
Sector median35.1×
 Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Trend
Sales7910280101103114138162171175180
Expenses648059777795104112121128126
Operating Profit1522212326193450504754
OPM %19%22%27%23%25%17%25%31%29%27%30%
Other Income1202512357183
Interest23556556587
Depreciation344445688910
Profit before tax1018131620212641454739
Tax %31%19%19%18%20%13%20%26%25%23%23%
Net Profit714111316182130343730
EPS in Rs2.375.233.233.863.733.874.287.036.876.866.67
Raw PDF

Earnings

Results dates & reactions
No upcoming results date on calendar.

Fresh quarters land in the Financials table above, tagged NSE until screener catches up.

Avg earnings-day move −6.24% · closed higher next day 0 of last 1
 Q1FY27
Broadcast27 Jul '26◦
Earnings day−6.24%
+1 day−6.64%
+5 days−3.65%
+15 days+8.89%
+30 days—
FilingXBRL

Corporate actions

Last 6 months

No recent corporate actions

Dividends, splits, and bonuses in the last six months show up here.

Results analysis

Shareholding

as of Jun 2026
45.82%Promoter
Promoters45.82%
FIIs6.62%2.98
DIIs9.77%0.15
Public37.78%3.14
Ownership trend

Peers

8 companies
Valuation vs quality
P/E × ROCE · bubble = market cap
NameCMPP/EMkt CapDiv YldNP QtrQtr Profit VarSales QtrQtr Sales VarROCE
SUNPHARMA₹1,895.0035.994,54,6740.84%2,901+5.95%15,300+10.46%20.53%
DIVISLAB₹9,315.0083.002,47,2840.32%902+65.50%3,080+27.80%21.97%
TORNTPHARM₹4,914.0083.771,86,9130.77%566+5.79%4,921+54.85%15.19%
ZYDUSLIFE₹1,156.9023.701,15,4010.09%990−35.09%8,017+21.96%21.14%
CIPLA₹1,395.0031.491,12,6960.93%786−39.19%7,119+2.33%15.49%
LAURUSLABS₹1,876.7092.741,01,4000.11%362+125.49%2,026+29.10%17.76%
LUPIN₹2,105.0016.1796,2540.86%1,417+16.08%8,277+32.04%29.93%
SENORES₹1,497.5054.576,8970.00%30+55.70%180+30.60%15.13%
Median: 159 Co.₹423.0035.072,2820.08%13+29.60%162+18.62%15.04%

Filings

Annual reports2
Annual Report 2026bseAnnual Report 2025bse
Concall transcripts23
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptJan 2026PPTJan 2026RECJan 2026PPTDec 2025TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptJul 2025PPTJul 2025RECJul 2025TranscriptMay 2025PPTMay 2025RECMay 2025PPTMay 2025TranscriptJan 2025PPTJan 2025RECJan 2025
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 4 Sep - We are enclosing herewith the Newspaper Publication for the 9th Annual General Meeting of the Company.Business Responsibility and Sustainability Reporting (BRSR) 3 Sep - Submitted BRSR report for FY 2025-26, covering ESG disclosures, governance, workforce, and environmental metrics.Reg. 34 (1) Annual Report. 3 SepShareholder Meeting To Be Held On September 25, 2026 At 11:30 Am (IST) 3 Sep - Senores Pharmaceuticals issued FY2025-26 annual report and AGM notice for September 25, 2026 at 11:30 A.M.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 27 Aug - Senores Pharmaceuticals Limited has informed regarding Analyst/ Institutional Investor Meet scheduled to be held on September 02, 2026